Apotex, which has been banned from selling its copycat version of the best-selling drug after releasing the product for 22 days last year, said in a statement it would immediately appeal the decision to the Federal Circuit.

“Despite today's decision, we are unwavering in our belief that the '265 patent will ultimately be held invalid and that the...